An observational study in Heart Valve Diseases and Moderate to Severe Valve Disease in the Elderly, sponsored by Yongjian Wu, MD, PhD. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Yongjian Wu, MD, PhD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Heart Valve Diseases with a site in China — 26 open to participants now, 28 under way, none of them phase 3. Heart Valve Diseases · China.
Among the 67 studies in Heart Valve Diseases with a site in China, this one is the 12th largest by planned enrollment of the 33 observational ones that give a count, is one of 6 that started in 2026, is one of 33 observational ones, reaches primary completion later than 15 of the 27 other live ones, and was the 67th registered.
554 studies on the registry are indexed under Heart Valve Diseases; 164 are open to participants now.
Browse Heart Valve Diseases studies →26 of the 67 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+ · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 118 Heart Valve Diseases studies recruiting now, 93 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 3
First in 2000; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,612 is above the median of 300 across 226 observational studies indexed under Heart Valve Diseases.
Median enrollment 200 across the 34 interventional studies, 2,644 across the 33 observational. Of the 18 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 67 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Yongjian Wu, MD, PhD as lead sponsor.
Yongjian Wu, MD, PhD has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Valve Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05397392Nanjing First Hospital, Nanjing Medical UniversityResearch on Optimal Diagnosis and Treatment of Cardiorenal Syndrome | 2026-12 |
| NCT07816146Yongjian Wu, MD, PhDChina Elderly Valve Disease Study III (China-DVD3 Study) | 2026-12-31 |
| NCT03011697Second Affiliated Hospital, School of Medicine, Zhejiang UniversityValvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 67 studies in Heart Valve Diseases with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to conduct a second round of multicenter, prospective registry research targeting elderly patients with valvular heart disease, to understand the current status of interventions for patients with valvular heart disease. To systematically evaluate the distribution of types, clinical characteristics, interventions, and complications of elderly valvular heart disease, and to compare and analyze these with the China-DVD data from 2016, thereby revealing its evolutionary trends. By comprehensively considering various clinical characteristics such as different types of valvular lesions, treatment modalities, patient cardiac function, comorbidities, and blood test indicators, as well as multidimensional factors including psychological and lifestyle aspects, to deeply identify the key determinants influencing the treatment of elderly valvular heart disease patients in China, and thus optimize and improve their individualized comprehensive management pathways.
This project is scheduled to be implemented from September to December 2026. It will consecutively enroll hospitalized patients with moderate and severe valvular heart disease across the original 69 national research centers of China-DVD, with the research protocol and definitions fully consistent with those in 2016.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospitalized patients over 60 years old meet one of the following conditions.
1、 moderate or above valvular heart disease as defined by echocardiography: One of the following criteria
Exclusion Criteria:
Patients unwilling to accept registration and follow-up;
This study aims to conduct a second round of multicenter, prospective registry research targeting elderly patients with valvular heart disease, to understand the current status of interventions for patients with valvular heart disease. To systematically evaluate the distribution of types, clinical characteristics, interventions, and complications of elderly valvular heart disease, and to compare and analyze these with the China-DVD data from 2016, thereby revealing its evolutionary trends. By comprehensively considering various clinical characteristics such as different types of valvular lesions, treatment modalities, patient cardiac function, comorbidities, and blood test indicators, as well as multidimensional factors including psychological and lifestyle aspects, to deeply identify the key determinants influencing the treatment of elderly valvular heart disease patients in China, and thus optimize and improve their individualized comprehensive management pathways.
First valve intervention during this hospitalization
Underwent their first internal medicine intervention or surgical procedure during hospitalization for valvular heart disease in this study
Time frame: From enrollment to the end of treatment at 12 weeks
1、Repeat valve intervention 2、Cardiovascular adverse events
1 、Repeat valve intervention : After the first valve intervention, the patient receives another valve surgical or interventional procedure due to valvular-related causes. 2、Cardiovascular adverse events : Any new-onset or recurrent cardiovascular disease, rehospitalization for cardiovascular reasons, and cardiac death, etc.
Time frame: From enrollment to the 12-month follow-up endpoint
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.
Of 95 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 3 months is below that.
Counting every sponsor, half of 115 studies reached it within 67 months; a quarter within 23 and three quarters within 212.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.